news
Lenzilumab™ significantly improves survival in hospitalised COVID-19 patients
In a Phase III trial, adding Lenzilumab™ to steroid and remdesivir regimens improved the likelihood of survival without need for mechanical ventilation by 54 percent.
List view / Grid view
Biologics
news
African Union to receive 220 million doses of Janssen COVID-19 Vaccine
The African Vaccine Acquisition Trust (AVAT) has entered into an advanced purchase agreement for 220 million doses of Janssen COVID-19 Vaccine.
news
GSK to provide fill and finish capacity for Novavax’ COVID-19 vaccine
Under a new agreement, GlaxoSmithKline will provide the fill and finish manufacturing capacity for 60 million doses of Novavax’ COVID-19 vaccine for use in the UK.
whitepaper
Article: A holistic strategy to ensure CCI of sterile vials
A framework to enable a holistic approach to CCI that assures both primary packaging and process contribute to good CCI of sterile vial product.
news
WHO issues alert for falsified COVID-19 vaccine
The World Health Organization (WHO) has warned that a falsified COVID-19 vaccine, identified as Pfizer’s BNT162b2, could still be in circulation in the Americas.
news
FDA approves Abecma, the first cell-based gene therapy for adults with multiple myeloma
Abecma (idecabtagene vicleucel) was approved for adults with relapsed or refractory myeloma based on its 72 percent overall response rate in a trial.
news
EMA approves increased manufacturing capacity for COVID-19 vaccines
The approval of at least one new manufacturing site based in Europe for each of the approved COVID-19 vaccines should increase supply for the EU.
news
AstraZeneca confirms COVID-19 vaccine efficacy with primary analysis
Following DSMB concerns about the data released regarding the Phase III US trial, AstraZeneca has now confirmed that its vaccine is 76 percent effective against symptomatic COVID-19.
news
EMA accepts regulatory submission for Takeda’s dengue vaccine candidate
The submission is the first in a series that will include dengue-endemic countries, it includes long-term Phase III safety and efficacy data for the TAK-003 vaccine candidate.
news
Could viral vector shortages disrupt the COVID-19 vaccine roll-out?
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
article
Why real-time environmental monitoring is the most important aspect of the modern pharmaceutical cold chain
Glenn Abood, founder and CEO of rfxcel, explains how real-time environmental monitoring can combat supply chain shortcomings, providing companies with level of data integrity, traceability, transparency and security that is virtually beyond reproach.
news
US finds COVID-19 Vaccine AstraZeneca safe and effective
An analysis of results from 20,000 vaccinnees shows AstraZeneca’s vaccine completely prevents severe or critical COVID-19 and hospitalisation.
news
REGEN-COV™ antibody cocktail reduces hospitalisation or death by 70 percent
Phase III data shows treatment with REGEN-COV™ (casirivimab and imdevimab) significantly reduces the risk of high-risk COVID-19 infected outpatients being hospitalised or dying.
news
Using albumin could facilitate vaccination by inhalation, finds pre-clinical study
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
article
How has COVID-19 impacted the development of cell and gene therapies?
European Pharmaceutical Review’s Hannah Balfour explores the findings of the Cell and Gene Therapy (CGT) Catapult’s 2020 advanced therapy medicinal product trials report and discusses how the European and global CGT markets are expected to perform in coming years.
